In this article, we will take a look at the 5 best low-priced growth stocks to buy. To see more such companies, go directly to 12 Best Low-Priced Growth Stocks To Buy.
5. ADMA Biologics, Inc. (NASDAQ:ADMA)
Number of Hedge Fund Holders: 21
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biotech company whose shares have shown a remarkable performance over the past 12 months, gaining about 80% in value. In March, ADMA Biologics, Inc. (NASDAQ:ADMA) posted its quarterly results. GAAP EPS in the period came in at -$0.06, beating estimates by $0.01. Revenue in the quarter jumped about 90% year over year to reach $49.95 million, beating estimates by $1.88 million. ADMA Biologics, Inc. (NASDAQ:ADMA) also said it expects to generate positive EBITDA by the second half of 2023.
At the conclusion of the fourth quarter of 2022, 21 hedge funds in Insider Monkey’s database of 943 hedge funds had stakes in ADMA Biologics, Inc. (NASDAQ:ADMA). The biggest hedge fund stakeholder of ADMA Biologics, Inc. (NASDAQ:ADMA) was Joseph Edelman’s Perceptive Advisors which had a $46 million stake in the company.
4. Zymeworks Inc. (NYSE:ZYME)
Number of Hedge Fund Holders: 24
Canadian biotech company Zymeworks Inc. (NYSE:ZYME) makes protein therapeutics to treat cancer and some autoimmune and inflammatory diseases. Zymeworks Inc. (NYSE:ZYME) ranks 4th in our list of low-priced growth stocks to buy. During the fourth quarter, Zymeworks Inc. (NYSE:ZYME)’s revenue jumped by a whopping 1900% year over year to total $402.49 million, beating estimates by $188.16 million. GAAP EPS in the period came in at $4.65, beating estimates by $2.16.
Wells Fargo recently gave a Buy rating and a $12 price target to Zymeworks Inc. (NYSE:ZYME). Wells Fargo cited Zymeworks Inc. (NYSE:ZYME)’s royalty streams and milestones from its lead oncology candidate.
3. Plug Power Inc. (NASDAQ:PLUG)
Number of Hedge Fund Holders: 25
Hydrogen fuel cell company’s Q4 revenue jumped 36% year over year but missed analyst projections. However, Plug Power Inc. (NASDAQ:PLUG) reaffirmed its revenue guidance of $1.4 billion for 2023. This revenue figure is above the analyst consensus of $1.36 billion.
Plug Power Inc. (NASDAQ:PLUG) recently announced it was selected by European power producer Uniper (OTC:UNPPY) to design the electrolyzer technology for the Maasvlakte Energy Hub at the Port of Rotterdam in the Netherlands.
2. Fate Therapeutics, Inc. (NASDAQ:FATE)
Number of Hedge Fund Holders: 25
Yet another biotech stock on our list, California-based Fate Therapeutics, Inc. (NASDAQ:FATE) makes cellular immunotherapies for cancer and immune disorders. In February, Fate Therapeutics, Inc. (NASDAQ:FATE) posted its Q4 results which were better than expectations. GAAP EPS in the quarter came in at -$0.58, beating estimates by $0.29. Revenue in the quarter increased by 160% year over year to total $44.34 million, beating estimates by $25.93 million.
As of the end of the fourth quarter of 2022, 25 hedge funds tracked by Insider Monkey had stakes in Fate Therapeutics, Inc. (NASDAQ:FATE). The biggest stakeholder of Fate Therapeutics, Inc. (NASDAQ:FATE) was Jeremy Green’s Redmile Group which had a $131 million stake.
1. Sunrun Inc. (NASDAQ:RUN)
Number of Hedge Fund Holders: 39
California-based Sunrun Inc. (NASDAQ:RUN) makes photovoltaic systems and battery energy storage products. During the fourth quarter, Sunrun Inc. (NASDAQ:RUN)’s revenue increased by 40% year over year to total $609.52 million, beating estimates by $20.63 million. GAAP EPS in the period came in at $0.29, beating estimates by $0.56.
Insider Monkey’s database of 943 hedge funds shows that 39 hedge funds had stakes in Sunrun Inc. (NASDAQ:RUN) as of the end of the fourth quarter of 2022.
You can also take a peek at 13 Best Medical Stocks To Invest In and 25 Most Exclusive Luxury Brands in the World.
